🇺🇸 FDA
Patent

US 11690860

Treatment of HCV infected patients with cirrhosis

granted A61KA61K31/7076A61K31/708

Quick answer

US patent 11690860 (Treatment of HCV infected patients with cirrhosis) held by Atea Pharmaceuticals, Inc. expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Atea Pharmaceuticals, Inc.
Grant date
Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
37
CPC classes
A61K, A61K31/7076, A61K31/708, A61P, A61P1/16